FoodApr 15, 2026
MEI YU CHENG DA TRADING Olive Skewers individually wrapped and packaged in clear recall — FDA H-0658-2026
Products contain banned sweetener: cyclamates.
Class IIIFDA: TerminatedMEI YU CHENG DA TRADING INC
Monthly breakdown
2026 recalls by month
Select a month to review the recall records reported during that period.
September 2026300 records · 4 categoriesAugust 2026302 records · 4 categoriesJuly 2026370 records · 4 categoriesJune 2026376 records · 4 categoriesMay 2026340 records · 4 categoriesApril 2026415 records · 4 categoriesMarch 2026190 records · 4 categoriesFebruary 2026331 records · 4 categoriesJanuary 2026212 records · 4 categories
2026 recalls — page 79
Records are ordered by the best available source date.
FoodApr 15, 2026
Pure Vitamins and Natural Supplements Red Bull Extreme Male Enhancement Supplement, total of recall — FDA H-0655-2026
FDA analysis revealed the presence of undeclared sildenafil
Class IFDA: OngoingPure Vitamins and Natural Supplements, LLC
FoodApr 15, 2026
MEI YU CHENG DA TRADING DADI NONGFU DRIED SALT CHILLI VEGETABLE recall — FDA H-0657-2026
Products contain banned sweetener: cyclamates.
Class IIIFDA: TerminatedMEI YU CHENG DA TRADING INC
FoodApr 15, 2026
Pure Vitamins and Natural Supplements Blue Bull Extreme Male Enhancement Supplement, total recall — FDA H-0654-2026
FDA analysis revealed the presence of undeclared sildenafil
Class IFDA: OngoingPure Vitamins and Natural Supplements, LLC
FoodApr 15, 2026
Riverence Provisions net wt recall — FDA H-0662-2026
Label declares cream cheese but does not declare milk
Class IIFDA: OngoingRiverence Provisions LLC
FoodApr 15, 2026
Zarlengo Italian Ice Zarlengo's Chocolate Chocolate Chip Gelato packaged in recall — FDA H-0650-2026
Soy Lecithin listed in ingredients statement, but Soy is not mentioned in the contains statement.
Class IIFDA: TerminatedZarlengo Italian Ice
FoodApr 15, 2026
Zarlengo Italian Ice Zarlengo's Double Dark Chocolate Gelato packaged in 1 Gallon recall — FDA H-0652-2026
Soy Lecithin listed in ingredients statement, but Soy is not mentioned in the contains statement.
Class IIFDA: TerminatedZarlengo Italian Ice
DrugApr 15, 2026
Lanreotide Injection, 120 mg*/0.5 mL, Box contains 1 Pre-filled syringe and 1 safety needle recall — FDA D-0422-2026
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
Class IIFDA: OngoingCipla USA, Inc.
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL), 1,000 recall — FDA D-0434-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
Fagron Compounding Services Vancomycin HCL, 1 gram added to 250 mL, 0.9% Sodium Chloride recall — FDA D-0442-2026
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Class IIFDA: OngoingFagron Compounding Services
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 250 mL recall — FDA D-0431-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 50 mL x60, Becton, Dickson and Company recall — FDA D-0429-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP 0.9% (450 mg per 50 mL) (9 mg per mL) 50 recall — FDA D-0425-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 1,000 recall — FDA D-0433-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
DEXTROSE 5% Dextrose Injection, USP 5 g per 100 mL (50 mg per mL) 100 mL in a 100 mL recall — FDA D-0436-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
DEXTROSE 5% Dextrose Injection, USP 12.5 g per 250 mL (50 mg per mL) 250 mL in a 250 mL recall — FDA D-0437-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
Clonidine Transdermal System, USP, 0.3 mg/day, supplied in cartons of 4 Systems and 4 recall — FDA D-0474-2026
CGMP Deviations: use of an unapproved raw material
Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc
DrugApr 15, 2026
DEXTROSE 5% Dextrose Injection, USP 2.5 g per 50 mL (50 mg per mL) 50 mL in a 100 mL recall — FDA D-0435-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Single dose only recall — FDA D-0423-2026
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
Class IIFDA: OngoingCipla USA, Inc.
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 100 mL recall — FDA D-0430-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
Fagron Compounding Services Vancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride recall — FDA D-0440-2026
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Class IIFDA: OngoingFagron Compounding Services
DrugApr 15, 2026
Clonidine Transdermal System, USP, 0.1 mg/day, supplied in cartons of 4 Systems and 4 recall — FDA D-0472-2026
CGMP Deviations: use of an unapproved raw material
Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, (4,500 mg per 500 mL) (9 mg per mL) 500 recall — FDA D-0428-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 0.9% (900 mg per 100 mL) (9 mg per mL) recall — FDA D-0426-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
About the 2026 recall archive
This archive groups records by their reported or recall date. It does not imply that every recall was initiated, announced and resolved during the same calendar year. Open the individual record for the exact dates and source details supplied by FDA or NHTSA.